NEW YORK (GenomeWeb News) – New Zealand cancer diagnostics company Pacific Edge said today its US Laboratory has achieved registration under the CLIA regulatory process, setting the stage for it to offer its bladder cancer test in the US.

CLIA registration means that Pacific Edge's laboratory in Hershey, Penn., will be able to operate and process urine samples from patients in the US for its laboratory-developed test called Cxbladder. The non-invasive, urine-based test uses molecular signatures to identify the presence of bladder cancer tumors.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: variant linked to canine cleft lip, new compression tool, and more.

GNC will start using DNA testing to authentic the presence of plants included in its labels, following an agreement with the New York Attorney General.

Fareed Zakaria writes that instead of focusing solely on STEM-related courses, students would do well to pursue the liberal arts if they want to be technology innovators.

A Harvard Business Review study found four major patterns of gender biases and added that black and Latina scientists further had to navigate racial stereotypes.